InsidersTradesSigma
Track the Pasithea Therapeutics Corp. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pasithea Therapeutics Corp. has logged 28 public disclosures. The latest transaction was reported on 22 June 2026 (Acquisition). Among the most active insiders: STEINMAN LAWRENCE. The full history is openly available.
28
Insider Decl.
n/a
Thresholds
€537,076
11 ops.
Buy Volume
€714
1 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 June 2026
Declarations28 total
100,000 sharesCommon StockSEC:0001104659-26-076184:0
Canonical exit: 15 Sept 2026 (T+90)
133,333 shares@ US$0.7567.0% of flowCommon StockSEC:0001213900-25-116309:0
Canonical exit: 26 Feb 2026 (T+90)
26,667 shares@ US$0.75100.0% of flowCommon StockSEC:0001213900-25-116306:0
33,333 shares@ US$0.7570.6% of flowCommon StockSEC:0001213900-25-116301:0
Canonical exit: 26 Feb 2026 (T+90)
33,333 shares@ US$0.7567.5% of flowCommon StockSEC:0001213900-25-116299:0
Canonical exit: 26 Feb 2026 (T+90)
33,333 shares@ US$0.75100.0% of flowCommon StockSEC:0001213900-25-116296:0
960 shares@ US$0.8258.0% of flowCommon StockSEC:0001213900-25-043621:0
750 shares@ US$5.61100.0% of flowCommon StockSEC:0001213900-24-053005:0
30,000 shares@ US$0.43128.3% of flowCommon StockSEC:0001493152-23-020333:0
Canonical exit: 31 Aug 2023 (T+90)
5,000 shares@ US$1.0054.1% of flowCommon StockSEC:0001213900-22-075490:0
5,000 shares@ US$0.9811.1% of flowCommon StockSEC:0001213900-22-075491:0
5,000 shares@ US$0.9911.4% of flowCommon StockSEC:0001213900-22-074585:0
10,000 shares@ US$1.07100.0% of flowCommon StockSEC:0001213900-22-073502:0
5,000 shares@ US$1.1012.8% of flowCommon StockSEC:0001213900-22-066554:0
600 shares@ US$1.087.4% of flowCommon StockSEC:0001213900-22-065571:0
1,000 shares@ US$1.11100.0% of flowCommon StockSEC:0001209191-22-054100:0
Canonical exit: 15 Jan 2023 (T+90)
1,000 shares@ US$1.142.7% of flowCommon StockSEC:0001213900-22-064401:0
57,647 shares@ US$1.18921.8% of flowCommon StockSEC:0001209191-22-051650:0
Canonical exit: 27 Dec 2022 (T+90)
55,646 shares@ US$1.125519.4% of flowCommon StockSEC:0001209191-22-048789:0
Canonical exit: 30 Nov 2022 (T+90)
5,000 shares@ US$1.16811.8% of flowCommon StockSEC:0001209191-22-048135:0
Canonical exit: 27 Nov 2022 (T+90)
54,644 shares@ US$1.2982100.0% of flowCommon StockSEC:0001209191-22-047714:0
Canonical exit: 17 Nov 2022 (T+90)
155,773 shares@ US$1.208757.0% of flowCommon StockSEC:0001493152-22-023502:0
Canonical exit: 15 Nov 2022 (T+90)
5,000 shares@ US$1.0250.5% of flowCommon StockSEC:0001213900-22-036296:0
5,000 shares@ US$1.0011.1% of flowCommon StockSEC:0001213900-22-035201:0
5,000 shares@ US$1.0049.5% of flowCommon StockSEC:0001213900-22-034621:0
25 of 28 declarations
关于 Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. 是一家在美国上市的生物技术公司，在纳斯达克（NASDAQ）上市，股票代码为KTTA和KTTAW。其主要行政办公室位于美国佛罗里达州迈阿密海滩。该公司成立于2020年，并于2021年9月完成首次公开募股（IPO）。随着时间的推移，Pasithea 从早期专注于中枢神经系统和精神/神经项目，转向更集中的开发策略，重点关注精准肿瘤学、RAS病和选定的罕见遗传病。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1841330/000121390025110093/ea0264188-10q_pasithea.htm?utm_source=openai)） Pasithea 的主要资产是PAS-004，这是一种下一代口服大环MEK抑制剂。该项目主要针对1型神经纤维瘤病（NF1），特别是丛状神经纤维瘤，并更广泛地用于MAPK通路驱动的肿瘤和其他RAS/MAPK相关适应症。该公司还描述了在携带已证实RAS、NF1或RAF突变的实体瘤患者以及先前BRAF/MEK抑制失败的患者中的潜在应用。实际上，Pasithea 现在是一家单一资产的临床阶段生物技术公司，因此投资案例几乎完全由PAS-004的临床和监管执行驱动。（[ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/116/pasithea-therapeutics-announces-completion-of-enrollment?utm_source=openai)） 从竞争角度来看，Pasithea 在一个高度拥挤且资本密集型的生物技术领域运营。大型制药和生物技术同行在资金、临床基础设施和监管经验方面具有显著优势。Pasithea 的差异化在于PAS-004的大环化学以及公司在耐受性、药代动力学和靶点参与方面建立形象的努力。然而，该公司仍然是一家处于开发阶段的微型市值公司，没有既定的商业收入基础，这意味着其股权故事本质上具有高风险，并且高度依赖未来的临床数据。（[ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/131/pasithea-therapeutics-announces-positive-pas-004-tablet?utm_source=openai)） 最近的里程碑对股票叙事至关重要。2025年，Pasithea 报告称开设了欧洲临床试验点，推进了其1期入组，并发布了积极的药效学和药代动力学中期更新，同时进行了公开融资以支持正在进行的开发。2026年4月，该公司宣布FDA授予PAS-004用于NF1的罕见儿科疾病认定，这是一个潜在有意义的监管信号，如果开发继续进展，可能会增强该项目的战略选择性。对于投资者而言，Pasithea 应被视为一家投机性的临床阶段生物技术公司，在获得积极数据的情况下具有显著的上涨潜力，但也伴随着早期药物开发商典型的融资稀释和执行风险。（[ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/111/pasithea-therapeutics-announces-opening-of-european?utm_source=openai)）
